● Recruiting

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Condition: Metastatic HER2 Positive Gastroesophageal Junction Cancer · Sponsor: Zhejiang Cancer Hospital

PhasePhase 1/Phase 2

Planned participants90

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This trial is An open-label, multicohort, multicenter clinical study aimed at evaluating the efficacy and safety of the cadonilimab combination regimen in the treatment of advanced HER-2 positive gastric/gastroesophageal junction tumors

This description comes directly from the study's public registry record.

Talk to the study team

Jieer Ying, MD · 13858195803 · jieerying@aliyun.com

Jieer Ying

Always discuss trial participation with your own doctor first.

Locations (1)

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06650332